We use privacy-friendly analytics. Read our privacy policy.

Compound Profile

Arabinoxylan

Glycemic response; gut microbiome; safety screen: IBS/FODMAP sensitivity; severe bloating.

Review needed — May worsen bloating in sensitive users; titrate fiber gradually. Details

Last reviewed: •1 source citedReport a correctionProfile-wide ·D Preliminary
Arabinoxylan monograph visual
Generated profile category visual

At a glance

From this profile's structured data
Evidence
Grade D
Safety
May worsen bloating in sensitive users; titrate fiber gradually.
Profile context
fiber_LDL
Next steps

Continue reading

Quick stats

Evidence level
Preliminary evidence
Typical onset
Varies by prep
Safety rating
Review needed: Safety review pending
Best for
Fiber LDL

Safety

Safety & Cautions

May worsen bloating in sensitive users; titrate fiber gradually.

Elevated caution

Caution level: Elevated. One caution category applies — read it before use.

Evidence Summary

Profile-wide ·D Preliminary

Evidence lens

Early signal that needs stronger human replication before practical claims.

PreliminaryPreliminary evidence

Human clinical evidence: Not the primary signal

Mechanistic / preclinical: Mechanism mapped — Metabolic Regulation · Vascular Function Support · Glucose Metabolism Support

Research maturity: Theoretical / mechanistic research — Mechanistic or unresolved evidence is kept separate from established human outcomes.

Safety boundary: Safety note available — May worsen bloating in sensitive users; titrate fiber gradually.

This profile cites 1 human study.

Evidence Strength

Confidence estimate based on the design quality and consistency of published clinical trials.

Preliminary evidence

Arabinoxylan has a preliminary evidence rating.

General wellnessGeneral wellness
Citation density
1.0
Sources
1
Effects
1
Research recency
Mixed recency
Evidence Grade

Grade D: Preliminary / Theoretical Evidence

Evaluation of methodological rigor, population reach, and evidence alignment.

Design Match
Randomized controlled trial
Risk of Bias
Low
Consistency
Not assessed
Strongest recorded design is a randomized controlled trial, drawn from 1 recorded study, 1 in people.
How evidence grades work

Each grade reflects the strength and consistency of published human evidence — not marketing claims. Grades are based on study count, design quality, effect size, consistency, and recency.

Strong
Multiple RCTs, consistent direction, adequate effect size
Moderate
Some RCTs or consistent observational data in humans
Preliminary / Mixed
Animal or in-vitro only, or conflicting human data
Traditional / Theoretical
Traditional use only; no controlled human trials
Clinical Study Summaries (1)0 human evidence sources · 0 human trials · Participant totals not consistently reported · Consistency not yet classifiable

What the evidence actually shows

This table contains 1 structured source, including 0 human evidence sources; 0 are human trials.

StudyDesignNDoseDurationPopulationOutcomeResult & magnitudeSource

Biobran/MGN-3, an arabinoxylan rice bran, enhances NK cell activity in geriatric subjects: A randomized, double-blind, placebo-controlled clinical trial

PubMed · Exp Ther Med · 2018

Background
Other / unclear

The study design is not yet classified clearly enough to infer its place in the evidence hierarchy.

——————PubMed →

How Arabinoxylan Works

Simplified mechanism pathway based on preclinical and pharmacological evidence. Does not confirm clinical efficacy.

Mechanism Pathway — How Arabinoxylan Works

How Arabinoxylan WorksArabinoxylan acts on biological target pathways via metabolic (regulation), leading to fiber ldl.ArabinoxylanBiological TargetBiological pathwayMetabolicRegulationFiber LdlObservable outcomeVascular FunctionSupport
CompoundTarget / ReceptorMechanismEffect / Outcome

Dosing

Common form
powder or capsule
No standardized dose
Our source data records the usual product form for this ingredient but no studied dose. Preparations differ widely, so follow the standardization on the product you actually have and speak to a clinician before starting.
Mechanisms & biological pathways

Preclinical mechanism details from scientific profiles; these represent plausible pathways but do not guarantee clinical efficacy in humans.

  • Metabolic Regulation
  • Vascular Function Support
  • Glucose Metabolism Support
  • Glucose Metabolism

Continue exploring

Related research paths

Compare & Sourcing

Compare side-by-side tradeoffs or verify active marker guidelines.

Free safety checklist

Get the Arabinoxylan evidence notes

Occasional research updates, safety context, and product-quality checks for supplement decisions.

We use your email to send the checklist and occasional evidence-first supplement updates. Unsubscribe anytime. Privacy policy.

Safety first · Harm reduction

This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.

Learn how we evaluate confidence, safety, and intensity on the methodology page.

Editorial Review

Checked against primary sources, cited evidence, and contraindication language before publication. Evidence claims, safety language, and affiliate modules are reviewed independently. Not personal medical advice.

Editorial Standards →

Help improve this profile

Was this useful for your research?

These controls record only the page and the structured choice you make when analytics consent is enabled. Please don’t include personal medical information in research requests.

Was this evidence summary clear?

Did you find what you were researching?